Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TruGamma System in Severe Tricuspid Regurgitation
NCT07691307Recruiting
- Sponsor
- Jiangsu Trulive Medtech
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in tricuspid valve regurgitation (TVR) (2 arms), sponsored by Jiangsu Trulive Medtech. Primary endpoints: Hierarchical composite endpoint including KCCQ, NYHA, and 6MWD at 12 months, Tricuspid Regurgitation severity at 12 months and 1 more. Started Mar 2026; status: recruiting.
02
Conditions
tricuspid valve regurgitation (TVR)
Beyond the preview
Go deeper on NCT07691307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691307.